Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Dietlein

Showing results (81-90 of 141) with videos related to

Pageof 15
Sort By:
Leukemia & Lymphoma|July 12, 2011
Role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisoneJana Markova, Deniz Kahraman, Carsten Kobe, et al.
Molecular Imaging and Biology|October 2, 2020
[<sup>18</sup>F]-JK-PSMA-7 PET/CT Under Androgen Deprivation Therapy in Advanced Prostate CancerFelix Dietlein, Peter Mueller, Carsten Kobe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2012
[18F]Fluorodeoxyglucose positron emission tomography/computed tomography-positive gastric adenocarcinoma in a 12-year-old girl with Peutz-Jeghers syndromeChristina Schneider, Thorsten Simon, Barbara Hero, et al.
Clinical Nuclear Medicine|October 3, 2012
Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer treated with erlotinibDeniz Kahraman, Arne Holstein, Matthias Scheffler, et al.
Molecular Imaging and Biology|August 9, 2021
Translational Development of a Zr-89-Labeled Inhibitor of Prostate-specific Membrane Antigen for PET Imaging in Prostate CancerSergio Muñoz Vázquez, Heike Endepols, Thomas Fischer, et al.
Plos One|December 21, 2018
Uptake in non-affected bone tissue does not differ between [18F]-DCFPyL and [68Ga]-HBED-CC PSMA PET/CTJochen Hammes, Melanie Hohberg, Philipp Täger, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 11, 2025
Association between metabolic tumor burden and health-related quality of life in patients with classic Hodgkin lymphomaMarie Lommen, Jasmin J Weindler, Janina Jablonski, et al.
Journal of Alzheimer'S Disease : JAD|January 24, 2022
Age and Anterior Basal Forebrain Volume Predict the Cholinergic Deficit in Patients with Mild Cognitive Impairment due to Alzheimer's DiseaseNils Richter, Lara-Sophia David, Michel J Grothe, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 30, 2021
An <sup>89</sup>Zr-Labeled PSMA Tracer for PET/CT Imaging of Prostate Cancer PatientsFelix Dietlein, Carsten Kobe, Sergio Muñoz Vázquez, et al.
Blood|September 1, 2018
Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphomaCarsten Kobe, Helen Goergen, Christian Baues, et al.
Pageof 15

Showing results (81-90 of 141) with videos related to

Sort By:
Pageof 15
Leukemia & Lymphoma|July 12, 2011
Role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisoneJana Markova, Deniz Kahraman, Carsten Kobe, et al.
Molecular Imaging and Biology|October 2, 2020
[<sup>18</sup>F]-JK-PSMA-7 PET/CT Under Androgen Deprivation Therapy in Advanced Prostate CancerFelix Dietlein, Peter Mueller, Carsten Kobe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2012
[18F]Fluorodeoxyglucose positron emission tomography/computed tomography-positive gastric adenocarcinoma in a 12-year-old girl with Peutz-Jeghers syndromeChristina Schneider, Thorsten Simon, Barbara Hero, et al.
Clinical Nuclear Medicine|October 3, 2012
Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer treated with erlotinibDeniz Kahraman, Arne Holstein, Matthias Scheffler, et al.
Molecular Imaging and Biology|August 9, 2021
Translational Development of a Zr-89-Labeled Inhibitor of Prostate-specific Membrane Antigen for PET Imaging in Prostate CancerSergio Muñoz Vázquez, Heike Endepols, Thomas Fischer, et al.
Plos One|December 21, 2018
Uptake in non-affected bone tissue does not differ between [18F]-DCFPyL and [68Ga]-HBED-CC PSMA PET/CTJochen Hammes, Melanie Hohberg, Philipp Täger, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 11, 2025
Association between metabolic tumor burden and health-related quality of life in patients with classic Hodgkin lymphomaMarie Lommen, Jasmin J Weindler, Janina Jablonski, et al.
Journal of Alzheimer'S Disease : JAD|January 24, 2022
Age and Anterior Basal Forebrain Volume Predict the Cholinergic Deficit in Patients with Mild Cognitive Impairment due to Alzheimer's DiseaseNils Richter, Lara-Sophia David, Michel J Grothe, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 30, 2021
An <sup>89</sup>Zr-Labeled PSMA Tracer for PET/CT Imaging of Prostate Cancer PatientsFelix Dietlein, Carsten Kobe, Sergio Muñoz Vázquez, et al.
Blood|September 1, 2018
Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphomaCarsten Kobe, Helen Goergen, Christian Baues, et al.
Pageof 15